US FDA Advisory Committee does not support approval of aducanumab for treatment of Alzheimer’s disease.

The majority of committee did not believe the EMERGE and PRIME studies provided strong evidence that supports the effectiveness of aducanumab, a monoclonal antibody, for the treatment of Alzheimer’s disease. A decision from FDA is expected by 07 March 2021.

Source:

Biospace Inc.